Many TherapeuticsMD, Inc.(TXMD) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. TherapeuticsMD Inc was Resumed by Jefferies on Nov 22, 2016 to Buy, Price Target of the shares are set at $18.TherapeuticsMD Inc was Initiated by Oppenheimer to Outperform on Nov 22, 2016.
Company has reported several Insider transactions to the SEC, on Mar 14, 2016, Cooper C. Collins (director) purchased 16,000 shares at 6.23 per share price.On Aug 27, 2015, Angus C. Russell (director) purchased 13,500 shares at 5.98 per share price.On Aug 24, 2015, Tommy G Thompson (director) purchased 10,798 shares at 6.29 per share price.
TherapeuticsMD Inc Last issued its quarterly earnings results on Nov 3, 2016. The company reported $-0.13 EPS for the quarter, missing the analyst consensus estimate by $ -0.01. Analyst had a consensus of $-0.12. The company had revenue of $5.50 million for the quarter, compared to analysts expectations of $5.64 million. The companys revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.11 EPS.
TherapeuticsMD, Inc. (NYSEMKT:TXMD) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1 by 4 Brokerage Firm. 4 Wall Street Firms have rated the stock as a strong buys.
TherapeuticsMD, Inc. (NYSEMKT:TXMD): According to 5 Analysts, The short term target price has been estimated at $ 15.5.The target price could deviate by a maximum of $2.78 from the forecast price. In the near term, the target price could hit a high of $18 and a low of $ 12.
TherapeuticsMD, Inc. (NYSEMKT:TXMD) rose 1.03% or 0.06 points on Tuesday and made its way into the gainers of the day. After trading began at $5.76 the stock was seen hitting $5.88 as a peak level and $5.76 as the lowest level. The stock ended up at $5.86. The daily volume was measured at 1,404,485 shares. The 52-week high of the share price is $9.29 and the 52-week low is $4.39. The company has a market cap of $1,152 million.
TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida.